ClinicalTrials.gg
CompletedNCT07734220Updated Jul 29, 2026

Evaluation of Two Heel Protection Devices to Assess Off-loading Via Pressure Mapping.

An observational study in Pressure Injuries, sponsored by Medline Industries. Completed at 1 site in United States. Open to participants aged 22 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Medline Industries · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
22 Years and older
Sex
All
01

Study summary

The goal of this trial is to compare heel off-loading capabilities of two products

Read the detailed description

Pressure injuries to the heel remain a major concern for immobile or limited mobility patients, as the heel is one of the highest risk sites for tissue breakdown. Offloading boots are widely used to redistribute lower extremity pressure and minimize concentrated forces at the heel. Internal Medline studies and industry literature reinforce the clinical relevance of pressure mapping to quantify heel offloading effectiveness across devices. Prior work has shown that heel offloading boots can differ widely in their ability to reduce pressure at the heel and ankle joint region. This study will quantitatively compare the heel off-loading capabilities of the Medline HeelMedix® Basic Heel Boot (hereafter referred to as HeelMedix® Basic) and the EHOB Foot Waffle Protector (hereafter referred to as EHOB Waffle) using pressure mapping in healthy volunteers. The data from this study design will allow for a comparative assessment of the heel offloading capabilities between two heel offloading boots.

02

Conditions studied

  • Pressure Injuries

Browse trials for

Keywords

  • pressure mapping
03

In context

Pressure Ulcer

545 studies on the registry are indexed under Pressure Ulcer; 129 are open to participants now.

This study's enrollment of 25 is below the median of 138 across 110 observational studies indexed under Pressure Ulcer.

Browse Pressure Ulcer studies →

Lead sponsor

Medline Industries is the lead sponsor of 39 studies on the registry; none are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Total number of participants, N=25

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individual is ≥ 22 years old
  • Self-reported to be in healthy condition.
  • Able to remain seated on a hard surface such as the floor and wear a heel protectant boot for at least thirty minutes.
  • Able to understand and willing to carry out instructions for this study.
  • Has a calf circumference of 11-19 inches

Exclusion criteria

Exclusion Criteria:

  • Self-reported to have pre-existing pathology associated with lower extremities
  • Individual has a calf circumference of less than 11 inches or greater than 19 inches
  • Individual is employed in a division of Medline Industries, LP under which the study product(s) are developed
  • Individual is sensitive to the materials of the study product(s)
  • Individual is considered inappropriate for inclusion by the principal investigator
  • Medline Contractors
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (actual)
Patient registry
No

Interventions

  • DeviceHeelMedix Basic & EHOB Waffle

    Participants will then have a baseline pressure mapping measurement taken, where they will be instructed to outstretch their right leg in front of them onto the BPMS pressure mat. The baseline peak and average pressures of the lower extremity in the heel, calf and combination of heel and calf as shown on the TekScan software connected to the mat will be recorded on the designated CRF. Pressure minimum and standard deviation will also be recorded. Once baseline measurements are complete, the first of two study devices will be applied to the participant, and they will place their leg back on the pressure mat in the same manner as the baseline measurement. Peak and average pressures of the lower extremity while wearing the first study device, in the heel, calf and combination of heel and calf as shown on the TekScan software connected to the mat will be recorded on the designated CRF. Pressure minimum and standard deviation will also be recorded. Steps will be repeated for 2nd device.

06

What researchers measure

Primary outcomes

  1. To evaluate heel offloading capabilities of two heel protection boot devices

    The primary endpoint will be the percentage change in peak and average pressures in the lower extremity (measuring heel, calf and combination)

    Time frame: 3-6 months

07

Study locations

1 site
  • Medline Industries, LP
    Northfield, Illinois 60093, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07734220
Lead sponsor
Medline Industries
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jul 8, 2026
Primary completion
Jul 22, 2026
Completion
Jul 22, 2026
Last update
Jul 29, 2026

Study contacts

Gregory J Gomez, RN BSN MPH
principal investigator · Medline Industries, LP

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion